C25-140

• Description :

  C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  E1/E2/E3 Enzyme; TNF Receptor

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/c25-140.html

• Purity :

  99.92

• Solubility :

  DMSO : 41.67 mg/mL (ultrasonic)

• Smiles :

  O=C(N1CCC(CC2=CC=CC=C2)CC1)CCC3=C(C)N(C4=NN5C(C=C4)=NN=C5C)N=C3C

• Molecular Formula :

  C26H31N7O

• Molecular Weight :

  457.57

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Brenke JK, et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J Biol Chem. 2018 Aug 24;293 (34) :13191-13203.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1358099-18-9]